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Introduction {#sec001}
============

The subthalamic nucleus (STN) is a small region located in the basal ganglia (BG) that is integral to a range of motor behaviors and cognitive functions \[[@pone.0214343.ref001]\]. Abnormal activity of the STN is implicated in a number of neurodegenerative and neurological disorders including Parkinson's disease (PD). Here, increased indirect pathway activity is thought to increase the inhibition of motor plans rather than reducing inhibitory control \[[@pone.0214343.ref002]\]. Accordingly, the STN is a common neurosurgical target for deep brain stimulation (DBS) for PD patients who no longer appropriately respond to pharmacological interventions, where standard targeting is facilitated by the use of MRI and stereotaxic atlases \[[@pone.0214343.ref003]\].

However, these atlases are often based on a normal population and fail to account for neuroanatomical variability occurring for a variety of reasons, including age and disease \[[@pone.0214343.ref004]--[@pone.0214343.ref009]\]. It is widely acknowledged that the anatomy of the STN varies substantially across healthy individuals, with *in-vivo* size estimates ranging from 50mm^3^ to 270mm^3^ (See \[[@pone.0214343.ref010]\] and references therein). Additionally, the STN has been shown to move with age, shifting in the lateral direction in the elderly population \[[@pone.0214343.ref011]--[@pone.0214343.ref014]\] with additional alterations of STN volume and location occurring in PD \[[@pone.0214343.ref015]\].

Moreover, the STN demonstrates a complex connectivity profile both within the BG and with the rest of the cortex \[[@pone.0214343.ref016]--[@pone.0214343.ref024]\]. With regards to PD, both the structural and functional connectivity of the STN has been shown to predict the future outcome and relative success of DBS treatment \[[@pone.0214343.ref025]\]. This is supported by electrophysiological and functional (f)MRI results which show that specific cortico-basal connections are functionally altered in PD \[[@pone.0214343.ref026]--[@pone.0214343.ref028]\]. Furthermore, the existing variability in the success of DBS suggests the presence of individual differences in the integrity of specific connections between the STN and different cortical regions.

DBS of the STN is however associated with a number of psychiatric side-effects, cognitive, and emotional disturbances \[[@pone.0214343.ref029],[@pone.0214343.ref030]\]. One explanation for these side-effects relates to the somatotopic arrangement of functionally dissimilar cortical projections within the STN \[[@pone.0214343.ref031]--[@pone.0214343.ref034]\]. In DBS, the implanted electrode may directly stimulate, due to suboptimal placement, or spread current to functionally disparate sub-regions of the nucleus which in-turn interfere with the typical connectivity between the STN and limbic or cognitive cortical areas \[[@pone.0214343.ref035],[@pone.0214343.ref036]\].

Given the neuroanatomical alterations that occur in the STN due to orthologic aging or PD, it is crucial to investigate whether additional group specific changes extend to their structural connectivity. The current paper first aims to investigate whether there are disease specific alterations in the connectivity of cortical areas to the subthalamic nucleus in PD patients by using group specific atlases of the STN, and second, to assess whether any connectivity measures may be correlated with disease progression. We chose six cortical areas based on their functional involvements in limbic, cognitive, and motor processes, known to be affected in PD \[[@pone.0214343.ref037]--[@pone.0214343.ref041]\]. Cortical areas consisted of the pars opercularis of the inferior frontal gyrus (Pop), the anterior cingulate cortex (ACC), the dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), supplementary motor area (SMA), and pre-supplementary motor area (pre-SMA). Notably, we use these results to highlight the importance of using group specific atlases for STN identification when ultra-high field (UHF) MRI is not available, given the scarcity of UHF MRI sites relative to the number of DBS centers \[[@pone.0214343.ref042]--[@pone.0214343.ref047]\].

Materials and methods {#sec002}
=====================

Subjects {#sec003}
--------

Seventy PD patients and thirty-one age-matched healthy controls participated in the study ([Table 1](#pone.0214343.t001){ref-type="table"}) (see \[[@pone.0214343.ref048]\] for more details on subject population). Patients were not required to discontinue their medication for the purposes of this study. The gender imbalance in the PD group was due to the fact that PD is 1.5 times more likely to occur in men than in women \[[@pone.0214343.ref049]--[@pone.0214343.ref051]\]. Disease related variables were obtained from PD patients, which include UPDRS III scores taken both on and off medication, duration of disease in years, and side of symptom onset (left or right), all obtained from an expert neurologist \[[@pone.0214343.ref052]\]. Disease progression, as a measure of severity, is calculated by dividing each patients UPDRS off III score by the duration of the disease in years \[[@pone.0214343.ref053]\]. Medication response is calculated by dividing the UPDRS off III score by the respective UPDRS on \[[@pone.0214343.ref054]\]. All healthy controls self-reported no history of psychiatric or neurological disease, and PD patients reported no other neurological complaints than PD. The study was approved by the ethical committee of the University Hospital of Cologne, Germany.

10.1371/journal.pone.0214343.t001

###### Descriptive statistics.

![](pone.0214343.t001){#pone.0214343.t001g}

  Measure                        Parkinson's Disease   Healthy Control
  ------------------------------ --------------------- ------------------
  **Age (years)**                62.01(*8*.*62*)       61.94(*10*.*21*)
  **Gender**                     54m/16f               25m/6f
  **Disease Duration (years)**   6.51(*4*.*64*)        \-
  **UPDRS III on**               14.46(*7*.*03*)       \-
  **UPDRS III off**              29.84(*12*.*18*)      \-
  **Symptom onset (side)**       33l/37r               \-

The means and standard deviations (S.D) demographic statistics for both the Parkinson's disease and healthy control group. UPDRS: Unified Parkinson's Disease Rating Scale.

MRI acquisition {#sec004}
---------------

Whole-brain anatomical T1-weighted and diffusion-weighted images were acquired for each subject with a Siemens 3T Trio scanner (Erlangen, Germany). T1-weighted images were obtained using a 12-channel array head coil with the following parameters: field of view (MDEFT3D: TR = 1930 ms, TI = 650 ms, TE = 5.8 ms, 128 sagittal slices, voxel size = 1 x 1 x 1.25 mm^3^, flip angle = 18°). dMRI images were obtained via a spin-echo EPI sequence with a 32-channel array head coil (spin echo EPI: TR = 11200 ms, TE = 87ms, 90 axial slices, voxel size = 1.7 mm isotropic, 60 directions isotropically distributed (b-value = 1000 s/mm^2^). Distortions due to eddy currents and head motion were corrected using FSL (Version 5.0; [www.fmrib.ox.ac.uk/fsl](http://www.fmrib.ox.ac.uk/fsl)) \[[@pone.0214343.ref055]\]. Additionally, to provide an anatomical reference for motion correction, seven images without diffusion weighting (b0 images) were acquired at the beginning and after each block per ten diffusion-weighted images. The diffusion-weighted images were then registered to these b0 images (see \[[@pone.0214343.ref048]\] for more details regarding the data acquisition).

Registration {#sec005}
------------

### MRI {#sec006}

All registration steps were conducted using both linear and nonlinear functions with FLIRT and FNIRT (as implemented in FSL version 5.0). All registrations were performed on skull stripped and brain extracted images. T1 weighted images were first linearly registered to the MNI152 T1 1mm brain template with a correlation ratio and 12 DOF. An additional nonlinear transform was applied using the FNIRT function with standard settings, including the previously obtained affine transformation matrix. Individual T1-weighted scans in native space were registered to the respective no-diffusion (b0) images with a mutual information cost function and 6 DOF. A standardized midline exclusion mask in MNI152 space was registered to each subjects b0 images through multiple transforms, by combining the transformation matrices outputted via previous registrations. The midline exclusion mask was visually checked and realigned with an additional registration if necessary. Each step during the registration process was visually assessed for misalignments by comparing several landmarks (ventricles, pons, corpus callosum, cortical surface).

### Cortical atlases {#sec007}

The six cortical areas were obtained from <http://www.rbmars.dds.nl/CBPatlases.htm>, created with tractography methods, based on both human and non-human primate neuroanatomy \[[@pone.0214343.ref056]--[@pone.0214343.ref058]\]. The separate cortical masks were extracted from MNI152 1mm space. The cortical atlases were thresholded at 25% to minimize the occurrence of over estimating the region during registration procedures, which were achieved with a nonlinear transform from MNI152 1mm to individual b0 space using the previously generated transformation matrices from the anatomical registrations, with a nearest neighbor interpolation and 12 DOF (see [Fig 1](#pone.0214343.g001){ref-type="fig"}).

![Cortical atlases.](pone.0214343.g001){#pone.0214343.g001}

Cortical atlases used for probabilistic tractography and the diffusion tensor models in MNI152 1mm space, which consist of the pars opercularis (POp), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), pre supplementary motor area (pre-SMA) and supplementary motor area (SMA).

### STN atlases {#sec008}

Group specific PD and elderly probabilistic atlases of the STN were obtained for the respective groups from \[[@pone.0214343.ref059]\] ([Fig 2](#pone.0214343.g002){ref-type="fig"}) (see <https://www.nitrc.org/projects/atag_pd/> for probabilistic atlases and ATAG data) and were transformed from MNI152 1mm space to individual b0 space using a nonlinear transform and thresholded by 25%. The non-zero voxel volume in mm^3^ for each atlas was as follows: PD left = 77; PD right = 70.13; HC left = 164.75; HC right = 138.38 and for the center of gravity (CoG) in MNI152 1mm space: PD left x = -10.44, y = -13.04, z = -8.16; PD right x = 11.84, y = -13.18, z = -89; HC left x = -10.56, y = -13.87, z = -7.10; HC right x = 12.10, y = -12.97, z = -6.20.

![STN atlases.](pone.0214343.g002){#pone.0214343.g002}

Representation of the group specific (left and right) subthalamic nucleus (STN) atlas in MNI152 1mm space where the Parkinson's sisease (PD) STN is in purple, and the healthy control (HC) is in orange.

Probabilistic tractography {#sec009}
--------------------------

Probabilistic tractography was run between *a priori* defined cortical areas and group specific STN's. Diffusion image preprocessing and analyses were achieved using FSL 5.0. The two most likely diffusion directions per voxel were estimated using the bedpostX function as implemented in the FDT toolbox with standard settings \[[@pone.0214343.ref060]\]. Subsequently, probabilistic tractography (probtrackX) was conducted to calculate continuous structural connections between the respective seed and target region(s). ProbrackX was run with standard settings (curvature threshold 0.2, 5000 samples, 0.5mm step length, 2000 steps) in each subjects' native diffusion space, separately for left and right hemispheres and aided by the inclusion of a midline exclusion mask.

The term tract strength is used here to index a probability density function, quantifying the ratio of how many streamlines directly and continuously commence from a seed region and terminate at a target area and vice versa (i.e. *seed to target / target to seed*). This density function is a commonly used measure for inferring the strength of structural white matter tracts \[[@pone.0214343.ref060]--[@pone.0214343.ref062]\]. For more robust measurements, we created an average of each pair of seed-to-target and target-to-seed streamlines \[[@pone.0214343.ref063],[@pone.0214343.ref064]\]. To control for spurious tracking, the tracts were thresholded by 10, whereby any voxel containing less than 10 direct samples were excluded from further analyses \[[@pone.0214343.ref064]\].

We calculated the axial diffusivity (AD), fractional anisotropy (FA), and mean diffusivity (MD) of the seed-to-target and target-to-seed paths derived from the tract strength probability density function approach mentioned in the above section. This was achieved by fitting a voxel wise diffusion tensor model with a weighted least squares regression to each subjects' diffusion image using the DTIFIT function from FDT. Each FDT path was thresholded so that only paths with at least 75 samples where included for further analysis to yield a conservative anatomical representation. Then each pair of corresponding paths were combined (seed-to-target and target-to-seed), binarized and averaged per hemisphere. From these normalized FDT paths we extracted the AD, FA, and MD values per tract, per subject.

Statistical methods {#sec010}
-------------------

All statistical analyses were conducted within a Bayesian framework ([Table 2](#pone.0214343.t002){ref-type="table"}) using the BayesFactor toolbox \[[@pone.0214343.ref065]\] in R \[[@pone.0214343.ref066]\], interpreted in light of the assumptions proposed by \[[@pone.0214343.ref067]\] and adapted by \[[@pone.0214343.ref068]\]. To test whether there were any group differences in either tract strength or DTI derived metrics \[[@pone.0214343.ref069]\], we used Bayesian ANOVAs. In this case, structure and tract strength or DTI metric are assessed for main effects and interactions, against the null. This results in four models, assessing for 1. Main effects of structure; 2. Main effects of group; 3. Main effects of both structure and group; and 4. An interaction between structure and group. Both subject and hemisphere were added as random factors, accounting for unequal sample sizes. BFs larger than 100, indexing decisive evidence for the alternative hypothesis, are noted as *\>100*. All analysis included default prior scales (maximum likelihood) and r-scale prior probabilities.

10.1371/journal.pone.0214343.t002

###### Bayes factor interpretation.
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  Bayes Factor          Interpretation
  --------------------- -----------------------------
  **\> 100**            Decisive evidence for H1
  **30--100**           Very strong evidence for H1
  **10--30**            Strong evidence for H1
  **3--10**             Substantial evidence for H1
  **1--3**              Anecdotal evidence for H1
  **1**                 No evidence
  **1 / 3--1**          Anecdotal evidence for H0
  **1 / 10--1 / 3**     Substantial evidence for H0
  **1 / 30--1 / 10**    Strong evidence for H0
  **1 / 100--1 / 30**   Very strong evidence for H0
  **\< 1 / 100**        Decisive evidence for H0

Interpretation of Bayes Factors. H1 refers to the experimental hypothesis, and H0 to the null hypothesis.

Our justification for using a Bayesian approach is that we are able to draw inferences on how likely our data is to reflect either the alternative hypothesis (H1) or the null (H0), whereas frequentist approaches using p-values as a significance criterion lead to a dichotomous decision as to whether the data is in support of H1 or H0. Relatedly, Bayesian approaches draw their distribution from the observed data, rather than requiring a Gaussian distribution, which can be difficult to meet with clinical datasets.

Since Bayesian approaches sample from the data itself, the priors for each group are calculated independently, whereby a smaller group will receive greater uncertainty than a larger group for comparison with no trade off with statistical power. Therefore, unequal sample sizes are not thought to negatively impact our results and should not reflect the size of the BFs reported \[[@pone.0214343.ref070],[@pone.0214343.ref071]\].

Where multiplicity adjustments are required, prior probabilities will be automatically updated. Generally speaking, the more plausible hypotheses there are, the lower the prior probabilities they will receive. However, Bayesian analyses will automatically prefer the simplest model if it explains the data just as well as a complex model with more parameters. Each test is performed independently of the others so we assume multiple comparisons are not a confounder in the present study\[[@pone.0214343.ref072]--[@pone.0214343.ref075]\].

To test whether disease progression correlated with either tract strength or the DTI derived metrics, we conducted Bayesian correlation analyses in JASP \[[@pone.0214343.ref073]\]. Disease progression and medication response were used as separate indices of disease severity \[[@pone.0214343.ref074]\]. All Bayesian tests used a non-informative prior and a medium sized distribution (conjugate distributions on either side).

Open science {#sec011}
------------

All scripts used to analyse the data can be found at <https://osf.io/4uxxs/>. The data is available upon request from the data protection officer of the Max Planck Society at the Max Planck Institute of Metabolism Research (representative: Dr Stefan Vollmar, <vollmar@sf.mpg.de>).

Results {#sec012}
=======

Group differences between HC and PD {#sec013}
-----------------------------------

### Demographics {#sec014}

Two samples Bayesian t-tests were conducted to assess for differences in age and gender across groups. For age, the BF~10~ of 0.23 indicates moderate evidence in favour of the null hypothesis as does a BF~10~ of 0.24 for gender. Therefore, we can assume that there is no difference in gender or age between groups and these variables are not included as covariates for further analyses.

### Motion parameters {#sec015}

Additional Bayesian t-tests were conducted to test for differences across groups in each of the directional (x, y, z) translation and rotation parameters, which index how much the subject moves during the MRI. All results were in favour of the null hypothesis (rotation x: BF~10~ = 0.51, rotation y: BF~10~ = 0.33, BF~10~ = 0.25, translation x: BF~10~ = 0.40, translation y: BF~10~ = 0.34, translation z: BF~10~ = 0.49). Accordingly, motion parameters are not included as a covariate in further analyses.

### Tract strengths {#sec016}

We first set out to test whether there were differences in tract strength between healthy control subjects and PD patients with a mixed effects ANOVA, incorporating subject and hemisphere as random factors (see [Fig 3](#pone.0214343.g003){ref-type="fig"} and [Table 3](#pone.0214343.t003){ref-type="table"}) and run with 50,000 iterations. When using group specific atlases of the STN, all models provide decisive evidence for the alternative, against the null (all BF~10~ = \> 100, ± \< 1.45%). The largest model included a main effect of group and structure, which is 197 times more likely than the model including an interaction. Therefore we can assume that while tract strengths vary across structure and group, they do not vary within structure across PD and HC, therefore no within group comparisons were conducted.

10.1371/journal.pone.0214343.t003

###### Tract strength descriptive statistics per tract, per group.
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  ---------------- ----------------- -----------------
  **Mean (S.D)**                     
  **Tract**        **HC**            **PD**
  **ACC**          0.28 (*0*.*19*)   0.21 (*0*.*17*)
  **DLPFC**        0.25 (*0*.*18*)   0.20 (*0*.*17*)
  **M1**           0.50 (*0*.*14*)   0.43 (*0*.*16*)
  **Pre-SMA**      0.66 (*0*.*08*)   0.56 (*0*.*16*)
  **SMA**          0.65 (*0*.*09*)   0.58 (*0*.*15*)
  **POp**          0.44 (*0*.*22*)   0.34 (*0*.*21*)
  ---------------- ----------------- -----------------

The means and standard deviations (S.D) of tract strengths for tracts running between the subthalamic nucleus (STN) and the pars opercularis (POp), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), presupplementary motor area (pre-SMA) and supplementary motor area (SMA), for Parkinson's disease subjects (PD) and healthy controls (HC).

![Tract strengths.](pone.0214343.g003){#pone.0214343.g003}

Tract strengths collapsed across hemisphere per structure (pars opercularis (POp), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), presupplementary motor area (pre-SMA) and supplementary motor area (SMA)), with healthy control (HC) subjects in orange and Parkinson's disease patients (PD) in purple. Tracts are measured from 0 to 1, which is representative of the ratio of the total number of tracts reported between the STN and the given cortical structure (and vice versa). Each point within each element represents a single subject. The width of each element represents the smoothed density. The columns overlapping each bar (each beginning at zero) represent the central tendency, and the bands overlapping each element reflect the 95% highest density intervals, and indicate that the tract strengths for PD are lower than healthy controls across all structures.

### DTI metrics: Group differences {#sec017}

To test whether there were group differences in the white matter composition, we extracted the AD, FA, and MD values of the six different tracts. Separate ANOVAs were run to assess AD, FA, and MD across groups ([Table 4](#pone.0214343.t004){ref-type="table"}), also with 50,000 iterations. For AD, the models including a main effect of structure, structure and group, as well as an interaction all provide decisive evidence for the alternative, against the null (all BF~10~ = \> 100, ± \< 1.4%). Though the model containing a main effect of only group provides anecdotal evidence for the null (BF~10~ = 0.36, ± 1.12%). The winning model, including a main effect of only structure was twice as likely than the second winning model, which included main effects of both structure and group. However, according to the interpretation, there is only anecdotal evidence for a difference between these models. Though the main effect of structure is decisively more likely by a BF~10~ of 283 than the model including an interaction. Therefore we can assume that while AD varies across structure and group, it does not vary within structure across PD and HC, therefore no within group comparisons were conducted.

10.1371/journal.pone.0214343.t004

###### Diffusion tensor imaging (DTI) descriptive statistics of axial diffusivity, fractional anisotropy and mean diffusivity per tract, per group.
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  Mean (S.D)                                                                                                                        
  ------------- ----------------------- ----------------------- --------------------- --------------------- ----------------------- -----------------------
  **ACC**       1.1e-03 (*5*.*1e-05*)   1.2e-03 (*4*.*5e-05*)   **0.40 (*0*.*02*)**   **0.39 (0.03)**       8.2e-04 (*5*.*0e-05*)   8.1e-04 (*5*.*0e-05*)
  **DLPFC**     1.2e-03 (*4*.*7e-05*)   1.2e-03 (*5*.*5e-05*)   **0.37 (*0*.*02*)**   **0.34 (*0*.*02*)**   8.6e-04 (*4*.*5e-05*)   8.6e-04 (*5*.*6e-05*)
  **M1**        1.3e-03 (*7*.*7e-05*)   1.3e-03 (*7*.*4e-05*)   **0.42 (*0*.*02*)**   **0.41 (*0*.*04*)**   8.8e-04 (*8*.*5e-05*)   8.8e-04 (*8*.*6e-05*)
  **Pre-SMA**   1.2e-0 (*5*.*0e-05*)    1.2e-0 (*5*.*0e-05*)    **0.40 (*0*.*02*)**   **0.39 (*0*.*03*)**   8.1e-04 (*5*.*2e-05*)   8.3e-04 (*5*.*2e-05*)
  **SMA**       1.3e-03 (*6*.*6e-05*)   1.3e-03 (*8*.*4e-05*)   **0.39 (*0*.*03*)**   **0.38 (*0*.*03*)**   9.2e-04 (*6*.*9e-05*)   9.3e-04 (*9*.*0e-05*)
  **POp**       1.3e-03 (*6*.*6e-05*)   1.2e-03 (*6*.*1e-05*)   **0.36 (*0*.*02*)**   **0.35 (*0*.*02*)**   9.3e-0 (*6*.*3e-05*)    9.4e-04 (*5*.*6e-05*)

Mean and standard deviations (S.D) for DTI metrics including axial diffusivity (AD), fractional anisotropy (FA) and mean diffusivity (MD) collapsed across hemisphere per structure (pars opercularis (POp), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), presupplementary motor area (pre-SMA) and supplementary motor area (SMA)) for healthy controls (HC) and Parkinson's disease patients (PD). FA values are marked in bold. There is evidence for group differences for the averaged FA values, which are lower in PD than HC.

MD models showed the same trend as the AD, whereby a main effect of structure, structure and group, as well as an interaction all provide decisive evidence for the alternative, against the null (all BF~10~ = \> 100, ± \< 2%). Though the model containing a main effect of only group provides moderate evidence for the null (BF~10~ = 0.14, ± 1.37%). The winning model, including a main effect of only structure is five times more likely than the second winning model, which included main effects of both structure and group. According to the interpretation, this is moderate evidence that the main effect of structure wins over a main effect of structure and group. Moreover, the main effect of structure is decisively more likely than the interaction by a BF~10~ of 167.

When assessing FA, all models provide decisive evidence for the alternative, against the null (all BF~10~ = \> 100, ± \< 2.9%). The winning model includes the interaction term, and is four times more likely than the second winning model which includes a main effect of structure group, and is decisively more likely than the model including only a main effect of structure by a BF~10~ of 833. Post-hoc Bayesian t-tests were run to assess for the evidence that structure by group differences was greater than zero. Here we find strong evidence for differences between groups for FA values between STN and POp by a BF~10~ of 18.53, with higher FA values for healthy controls than PD patients. Substantial evidence was found for FA values differing across groups between the STN and the ACC (BF~10~ = 3.05), which are also higher in healthy controls than PD patients. Decisive evidence was found for the DLPFC (BF~10~ = 5.31e+10) and pre-SMA (BF~10~ = 68.31) connectivity profiles, again both with higher FA values for healthy controls than PD patients ([Fig 4](#pone.0214343.g004){ref-type="fig"}). Anecdotal evidence was found for lower FA for the SMA connectivity profiles in PD than HC (BF~10~ = 2.35).

![Fractional anisotropy pathways.](pone.0214343.g004){#pone.0214343.g004}

Averaged and thresholded fractional anisotropy (FA) tracts per group running between the subthalamic nucleus (STN) to the pars opercularis (POp), anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), and pre supplementary motor area (pre-SMA), with Parkinson's disease (PD) tracts in purple and healthy control (HC) tracts in orange. In all tracts, the FA was lower for PD compared to healthy controls.

### Correlations {#sec018}

Bayesian paired correlations with a Pearson's Rho correlation coefficient was conducted to assess whether for each PD patient, disease progression or medication response correlated with either their tract strength or respective FA measures \[[@pone.0214343.ref073]\]. Additionally, because the motor related symptoms of PD often begin and continue to exhibit asymmetrically, the side in which symptom onset was first identified (i.e., left or right side of the body) was counterbalanced across hemisphere \[[@pone.0214343.ref076]--[@pone.0214343.ref078]\]. Symptom onset initiating on the left side of the body was paired with tract strength or FA values arising from the right hemisphere and vice versa for the left hemisphere (contralateral), and a separate correlation test was conducted for those tracts that occur in the hemisphere on the same side as symptom onset (ipsilateral). This was done in order to control for the lateralization effects of both symptom presentation and brain connectivity and to test whether tract strengths can act as an index of symptom severity.

For disease progression with tract strength, all results reported substantial evidence for no correlation between tract strengths and disease progression. For medication response with tract strength, all results reported anecdotal (ACC) or substantial (DLPFC, M1, pre-SMA, SMA, POp) evidence for no correlation between tract strengths and medication response. For disease progression with averaged FA, the only a tract to show strong evidence of a correlation with disease progression was the DLPFC ipsilateral score (r = 0.35, BF~10~ = 16.50), where side of symptom onset and hemisphere were the same. All other results reported either anecdotal or substantial evidence for no correlation between FA and disease progression. For medication response with averaged FA, all results reported substantial evidence for no correlation between FA and medication response. See the [S2 File](#pone.0214343.s002){ref-type="supplementary-material"} for the full results of the correlation analysis.

Discussion {#sec019}
==========

The current study assessed the strength and microstructural changes occurring in predefined connectivity profiles between the STN and motor, limbic, and cognitive related cortical areas between PD patients and healthy elderly age-matched controls using group specific atlases of the STN.

PD Disease specific alterations {#sec020}
-------------------------------

For all six cortical areas, the mean tract strengths were lower for the PD group, however there was no statistical evidence to support substantial differences compared to healthy controls. Moreover, none of the tract strengths between the STN and the cortical areas correlated with measures of disease progression or medication response. It therefore appears unlikely that the strength of any of the measured tracts may be used as a biomarker for PD.

Diffusion tensor models were applied to draw quantitative measurements of each white matter tract. For the original analysis, we found evidence for a reduction in FA for the STN to POp, ACC, DLPFC, and pre-SMA tracts in PD patients compared to healthy controls. The POp is situated anterior to the premotor cortex and has been implicated in motor inhibition \[[@pone.0214343.ref079]\] which is referred to as the ability to suspend a premeditated motor response to a stimulus or an ongoing response \[[@pone.0214343.ref080]\]. It has also been proposed that the POp is the origin of "stop signal" behaviors, whereby the inhibition of a motor response results from direct stimulation of the subthalamic nucleus \[[@pone.0214343.ref081]\]. Moreover, the primary STN-ACC circuit functions to monitor behaviors that involve conflict and therefore task switching and changing decisions \[[@pone.0214343.ref082]--[@pone.0214343.ref084]\]. Structural and or functional alterations within the STN-POp and ACC connectivity profiles could reflect the symptomatic profile of PD \[[@pone.0214343.ref085],[@pone.0214343.ref086]\].

Relatedly, associated functions of STN-pre-SMA circuit also include response inhibition \[[@pone.0214343.ref087]\], action choices \[[@pone.0214343.ref088]--[@pone.0214343.ref090]\], task switching and internally generated movements \[[@pone.0214343.ref091],[@pone.0214343.ref092]\], which are shown to be disrupted in PD. Assuming structure both shapes and constrains function \[[@pone.0214343.ref093]--[@pone.0214343.ref095]\], compromised white matter tracts indexed by increased diffusivity and reduced FA could result in abnormal functioning and lead to clinically overt behaviors \[[@pone.0214343.ref096]\]. A dysfunctional STN-pre-SMA circuit could result in parkinsonian symptoms including micrographia, dysarthia, bradykinesia and hypokinesia, all of which involve a lack appropriate action selection, timing, and irregular task switching \[[@pone.0214343.ref097]--[@pone.0214343.ref099]\]. A dysfunctional STN-DLPFC circuit could reflect impaired motor control, PD related cognitive decline, and affective complaints \[[@pone.0214343.ref100]--[@pone.0214343.ref102]\] as well as being linked to dopaminergic abnormalities \[[@pone.0214343.ref103]\]. However, while reduced FA in specific STN-cortical circuits could be utilized as a biomarker for PD, it is difficult to infer the exact biological mechanisms underlying alterations in diffusion metrics relative to disease. FA has been considered as a summary measure of white matter integrity, that is highly sensitive to microstructural changes, but less sensitive to the type of change \[[@pone.0214343.ref104]--[@pone.0214343.ref107]\], though theoretically, a reduction in FA could be driven by a singular or combination of altered AD, MD, or radial diffusivity.

Moreover, white matter consists not only of axons, but oligodendrocytes, astrocytes and microglia and therefore structural changes can affect any of these properties, each of which is associated with a different function \[[@pone.0214343.ref108],[@pone.0214343.ref109]\]. Studies have shown that FA correlates with myelination which is associated with speed conduction, though this is dependent on the formation and remodeling of oligodendrocytes and differentiation of oligodendrocyte precursor cells (OCPs) whose function is to determine the production, length and thickness of internodes and therefore also likely to contribute to the FA signal \[[@pone.0214343.ref110]--[@pone.0214343.ref113]\]. Fewer studies have assessed diffusion parameters in relation to astrocytes, though their contribution to FA signals is likely to be significant given their large occupying volume within both grey and white matter \[[@pone.0214343.ref112],[@pone.0214343.ref114]\].

Physiologically, a disruption or structural abnormality occurring anywhere along the axon, for example due to changes in myelination, impaired astrocyte propagation or suboptimal OCP proliferation and differentiation, would impede the rate of conduction and transmission between structures and consequently result in functional impairments \[[@pone.0214343.ref115]\]. Additionally, more widespread changes in myelin and internode plasticity can be driven by region-specific mechanisms \[[@pone.0214343.ref116],[@pone.0214343.ref117]\]. In the case of PD, local signals arising from dopaminergic cell loss with the substania nigra, or the pathological hyperactivity of the STN could drive the observed structural changes in cortico-basal white matter connections. However, due to the complex timeline and microscopic spatial resolution of these neurochemical and anatomical changes, it is currently not possible to identify which process corresponds with in-vivo human dMRI based FA measures.

Further, diffusivity has been correlated with partial voluming effects arising from free-water \[[@pone.0214343.ref118]\]. Free-water reflects the presence of water molecules that are not restrained by cellular barriers and therefore do not show a preference for direction, which may be increased in the presence of cellular damage \[[@pone.0214343.ref119]\]. Thus, the presence of free-water may influence biases on diffusion metrics which can result in a reduction in FA and or an increase in MD \[[@pone.0214343.ref120],[@pone.0214343.ref121]\]. For instance, free-water present in diffusion has been shown to reflect FA changes occurring in other PD affected areas such as the substantia nigra \[[@pone.0214343.ref122],[@pone.0214343.ref123]\]. Additionally, the measure of tract strength was taken via a probability density function (PDF), which despite being shown as a robust assessment, remains controversial. Measurements indexing relative strength via dynamic causal models, may offer additional information for instance by using tractography data to set priors for connection strengths between regions \[[@pone.0214343.ref124]\].

Correlates of PD disease severity {#sec021}
---------------------------------

Overall, we found no evidence for any correlation between either tract strengths or FA values with disease progression or medication response. With one exception, we found a positive correlation for FA values within the STN-DLPFC connectivity profile increasing with disease progression when the side of symptom onset was matched with hemisphere. An increased FA indicating restricted diffusion along a single direction is not necessarily compatible with explanations of neurodegenerative processes when assuming a higher FA implies increased myelination and axonal density which usually decrease with disease progression. It may be possible that the increased FA is explained by an attempted compensatory, neuroplasticity mechanism and or functional reorganization rather than a direct neurodegenerative process \[[@pone.0214343.ref125],[@pone.0214343.ref126]\], or a response to atypical dopaminergic modulation and levodopa intake \[[@pone.0214343.ref127]--[@pone.0214343.ref129]\]. Such an adaptive reorganization of structural and functional pathways would, however, occur long before the onset of clinical symptoms, which is not in line with the rather progressed stage of the PD population within this study \[[@pone.0214343.ref076],[@pone.0214343.ref078]\]. We therefore remain speculative as to the explanation of this result.

Considerations {#sec022}
--------------

The use of MRI poses several challenges when imaging small subcortical nuclei such as the STN \[[@pone.0214343.ref130]\]. In the current study, the resolution of the anatomical and diffusion sequences was rather large when considering the size of the STN \[[@pone.0214343.ref131]\]. Imaging the STN is subject to partial voluming effects and blurring of the voxels near the borders of the nucleus, which may contain different tissue types and or fiber bundles of neighboring structures \[[@pone.0214343.ref024],[@pone.0214343.ref132]\]. This is further complicated by probabilistic atlases being inherently larger than is often anatomically exact and require registration between template and native space. Such registration procedures employ simple scaling factors that can fail to optimally incorporate morphometric and densitometric variability between individuals \[[@pone.0214343.ref133]\] which can in turn affect the accuracy of subsequent analysis. We account for this by using group specific atlases, thresholding atlases, and incorporating both rigid and affine transformations during registration procedures. In the [S1 File](#pone.0214343.s001){ref-type="supplementary-material"} we included a number of additional analysis to investigate the effects of atlas accuracy.

Manual segmentation of the both the STN and cortical areas for all individuals would be the golden standard, however, the data in the current study did not allow for manual parcellation of the STN or of structurally distinct cortical areas \[[@pone.0214343.ref134],[@pone.0214343.ref135]\]. Relatedly, the visualization of the STN would benefit from the use of sub-millimeter resolution imaging with UHF MRI and/or susceptibility-based contrasts \[[@pone.0214343.ref013],[@pone.0214343.ref136]\].

Lastly, we do not assess for gender differences. While sexual dimorphisms in PD have been reported \[[@pone.0214343.ref050],[@pone.0214343.ref099],[@pone.0214343.ref137],[@pone.0214343.ref138]\], it remains controversial as to how sensitive standardized scores such as the UPDRS are at identifying gender differences \[[@pone.0214343.ref137],[@pone.0214343.ref139]\]. In addition, we include a relatively small sample size with an unbalanced male to female ratio.

Conclusions and future directions {#sec023}
---------------------------------

To conclude, the strength of white matter tracts within the hyper-direct pathway appear unaffected by the pathophysiology of PD. However, decreased FA values of the STN-POp, STN-DLPFC and STN-pre-SMA tracts may be used as a biomarker for disease, though the exact biological mechanisms driving these disease specific alterations in FA remain elusive. Regardless, the differences we find are in the connections to cortical areas involved in preparatory motor control, task monitoring and decision making, rather than cortical areas governing motor output. Further, the results indicate that it is recommended to use an atlas that accounts for anatomical changes associated with PD rather than only age matched controls. See the [S1 File](#pone.0214343.s001){ref-type="supplementary-material"} for a control analysis to support the use of group specific atlases. Future work should focus on the use of higher field strengths, alternative tractography methods and harmonization of techniques used to investigate PD \[[@pone.0214343.ref140],[@pone.0214343.ref141]\]. Until then, we show that using atlases that are specific to your population can aid analysis where UHF MRI and or manual segmentations are not possible.

Tractography methods hold great promise for their contribution to identification of disease, differential diagnoses between subtypes of parkinsonian syndromes and the application of DBS \[[@pone.0214343.ref142],[@pone.0214343.ref143]\]. Such applications require assessment of the biological foundations of diffusion metrics and neuroanatomical factors with specific subsets of disease scales used to evaluate presence and severity.

Supporting information {#sec024}
======================

###### Control analysis.

Fig A. STN Atlases. Subthalamic nucleus (STN) atlas in MNI152 1mm space where the Parkinson's disease (PD) STN is in purple, and the healthy control (HC) in orange. The first control analysis is shown where the group specific atlases were switched so that the PD STN was registered to each HC, and vice versa. The last image shows the second control analysis where spheres were derived from the group specific center of gravity coordinates and expanded by 4.5mm. Table A. Tract strength descriptive per tract, per group, for the first control analysis which switches group specific atlases. Fig B. Tract Strengths: First Control Analysis. Tract strengths for the first control analysis, collapsed across hemisphere per structure, with healthy control (HC) subjects in orange and Parkinson's disease (PD) patients in purple. Table B. Tract strength descriptive per tract, per group, for the second control analysis which uses spherical ROIs as an atlas. Fig C. Tract Strengths: Second Control Analysis. Tract strengths for the second control analysis, collapsed across hemisphere per structure, with healthy control (HC) subjects in orange and Parkinson's disease (PD) patients in purple. Table C. Diffusion Tensor Imaging (DTI) descriptive statistics of axial diffusivity, fractional anisotropy and mean diffusivity per tract for the first control analysis. Table D. Diffusion Tensor Imaging (DTI) descriptive statistics of axial diffusivity, fractional anisotropy and mean diffusivity per tract, per group for the second control analysis.
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###### 

Click here for additional data file.

###### Correlation results.

Table A. Pearson's Rho. Interpretation of Pearson's Rho Correlation Coefficients\[[@pone.0214343.ref001]\]. Table B. Correlation between disease progression and tract strength. Table C. Correlation between medication response and tract strength. Table D. Correlation between disease progression and fractional anisotropy. Table E. Correlation between medication response and fractional anisotropy.
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###### 

Click here for additional data file.
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